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Our mission
Organovo is focused on delivering 
breakthrough three dimensional 
biology capabilities to create tissue 
on demand for research and 
surgical applications.
NovoGen Tissue Printing Is A Novel Proprietary Process
To Create Biological Constructs
Organ Printing is machine printing of cells
Using “bio-ink” – spheres of cells
…enabling the formation of biological,
native structure, autologous tissue
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• Spheres fuse to form final tissue 
• Able to print simple tissues today
• Create 3D cell environments
• Current successful structures: tubes, 
cylinders, sheets
• Start with any adherent cell type
• Aggregate spheres formed
• 100-500 µm, ~103-104 cells each
• Bioprinter places cell spheres into 
pattern
NovoGen MMX Is Organovo’s Proprietary
Bioprinting System
Challenges in the field…
…easy to use modular NovoGen bioprinters 
have been developed
• Most tissue engineering requires 
scaffold for structural support; useful 
polymers can be difficult to find
• Scientists need highly accurate method 
to create 3D cellular environment
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• Many cell types do not grow well in 
standard 2D conditions
• Need gradient to study cell behavior in 
response to conditions
• Need automated process to reduce 
variability of manual processing
NovoGen MMX Bioprinter
• Can create tissue from cells alone
• Ability to deposit semi-solid droplets to 
create 3D structures
• Suitable for many cell and gel types
• Proprietary software with intuitive 
programmable features
• Supports sterile production*
* Requires only low cost Level II Biosafety Cabinet
Architecture of Conduit Constructs Based on Scaffold Free Bioprinting 
Method
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Organovo’s NovoGen Bioprinting is based on a scaffold free bioprinting 
process.  The cellular “inks” are supported architecturally by hydrogel.  
The hydrogel can later be removed, thus leaving only the 3D cellular 
structure.  The system allows deposition of any structure; traditional 
challenges like diffusion must be considered to keep tissues viable.
Bioprinted Constructs Have Been Shown to Quickly Build Collagen
Day 0 Day 10
Tube inside hydrogel prior to full fusion
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Bioprinted vascular construct in perfusion
bioreactor; collagen builds and burst pressure
grows over ten days after attachment
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5 year Multi-institutional project
Organovo’s Team Brings Together the Expertise 
and Drive Required for Success
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Gordana Vunjak-Novakovic, PhD – Columbia University
Professor of Biomedical Engineering, Columbia University
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Organovo’s SAB Is a Key Contributor to 
Scientific and Clinical Success
Co-wrote the text on cell culture in tissue engineering
Glenn Prestwich, PhD – University of Utah
Professor of Chemistry (Biomaterials)
Accomplished entrepreneur (Four biomedical companies 
launched)
Craig Kent, MD – Chief of Surgery, Univ. Wisconsin
Former Chairman, Society for Vascular Surgery
Extremely well published in vascular biology
Well funded preclinical research lab
Site of significant preclinical work for Organovo
Organovo is Focused on Developing Product Pipeline to Fully Leverage 
the Ability to Organ Print
Therapeutic 
Tissues
Nerve Graft
Bioprinting 
Solutions
Big Pharma 
Partnerships
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Cardiac Muscle
Cartilage
Research Tools 
for Tissue 
Engineering
Cell Biology 
Models
Nerve Conduit1 (2012-2013)
Cartilage Graft2 (2012-2013)
Organovo is Focused on A Strong Pipeline of
Simple Tissue Geometries that Can Move Quickly to Market
Product (Clinical study dates)
Blood Vessels1 (2012-2013)
Cardiac Muscle2 (2014)
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1 Current areas of preclinical development
2 Area with low cost path to proof of concept
Blood vessel indications: Peripheral Bypass &
Dialysis AV Access
TBTBDY
Organovo Has Significant Qualitative and 
Quantitative Market Research on Key Markets
Nerve Conduit Provides $1B 
Early Access Market
• Significant negatives to sural nerve harvest for autograft
• Current Synthetic conduits have limited utility
• Can be useful in over 1/3 of current surgeries
• Additional opportunities in peripheral neuropathy
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“Synthetic conduits can’t be 
used in any gap larger than 
2-3 cm”
Comments from neurosurgeons:
“Current nerve harvest is a long 
process and leaves permanent 
deficit  for the patient”
MRE:RSG
Organovo Has Used The Past 18 Months and Initial Seed Funding
to Make Major Strides
• Moved operations forward – opened site in San Diego, tech 
transfer from University of Missouri
• Advanced the science – Two NIH SBIR grants, animal 
studies by U. Missouri, blood vessel proof of concept trial 
design w/U. Wisconsin, primary human cells in use
• Established Bioprinter Market – Developed award-winning 
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• Confirmed the market – Quantitative and 
qualitative market research that gives us very 
high confidence in our plan
• Created partnership opportunities – First 
big pharma deal inked, others in discussions
NovoGen MMX Bioprinter; sales increasing steadily
TBTBDY
Organovo Seeks a Global Presence with 
National Centers of Excellence
US Australia
Japan Germany,
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MRE:RSG
EU
Singapore
Breakthrough science.
Demonstrated market need.
The experience to deliver on the promise.
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